JNJ - Johnson & Johnson
147.25 -0.05 (-0.03%)
After hours: 6:05PM EDT
| Previous close | 146.73 |
| Open | 147.69 |
| Bid | 147.14 x 1000 |
| Ask | 147.19 x 800 |
| Day's range | 146.60 - 149.64 |
| 52-week range | 109.16 - 157.00 |
| Volume | 7,033,977 |
| Avg. volume | 11,211,204 |
| Market cap | 388.334B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 28.09 |
| EPS (TTM) | 5.24 |
| Earnings date | 16 Jul 2020 |
| Forward dividend & yield | 4.04 (2.75%) |
| Ex-dividend date | 22 May 2020 |
| 1y target est | 164.17 |
- Motley Fool
Legend Biotech's IPO Blows Past Expectations
On Friday, Legend Biotech (NASDAQ: LEGN) became the latest biotechnology start-up to pull off a surprisingly successful initial public offering. The cell-based cancer therapy developer originally intended to raise around $350 million, but investors eager to invest in a corner of the economy relatively unaffected by the COVID-19 pandemic piled in and pushed Legend's haul up to a stunning $424 million.
- Yahoo Finance
Coronavirus update: Payrolls spark hope for a fast rebound as Novavax gets a boost in vaccine race
Stunning employment data fed into growing optimism about cities and states relaxing the coronavirus-related restrictions that have hobbled activity and crushed the jobs market.
- Zacks
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
- Motley Fool
Report: Trump Administration Picks 5 Coronavirus Vaccine Candidates to Support
The White House reportedly plans to route extra federal funds and other assistance to the companies developing those potential SARS-CoV-2 vaccines.
- Motley Fool
Emergent BioSolutions Picks Up a "Warp Speed" Contract to Manufacture Coronavirus Vaccines
The contract development and manufacturing organization will support a number of SARS-CoV-2 vaccine candidates.
- Zacks
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $148.25, marking a +0.72% move from the previous day.
- Motley Fool
Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?
- Motley Fool
3 Great Stocks for Low-Risk Investors
Investing in stocks is risky. The company claims to be "one of the few future-proof stocks" available today. It's a pretty safe bet that energy will increasingly be produced using renewable sources such as hydroelectric, wind, and solar.
- Motley Fool
If You Invested $10,000 in Johnson & Johnson’s IPO, This Is How Much Money You'd Have Now
Wouldn't it have been great to get in on the ground floor of Johnson & Johnson? How much money would you have now if you had been in that group and invested $10,000 in J&J? Twenty years before Mick Jagger, Keith Richards, and the rest of the band released that song, Johnson & Johnson listed its shares on the New York Stock Exchange.
- Motley Fool
Here’s How to Find the Best Dividend Stocks
Before putting your money in a dividend stock, you'll want to make sure it meets certain criteria. Let's look into how to identify great dividend stocks, and then we'll turn our attention to one stock that's a great choice for income-seeking investors. There are several dividend-specific metrics to consider when looking for great dividend stocks.
- Reuters
J&J's Ebola vaccine wins EU regulatory panel backing
J&J submitted its application to the European Medicines Agency (EMA) in November for the vaccine, which targets an Ebola strain that causes the disease in most people. The company in February said it was developing a coronavirus vaccine program with the help of the same technologies used in the experimental Ebola vaccine. The panel recommendation confirms the potential of the vaccine technology, Johan Van Hoof, managing director of J&J's Janssen unit said.
- Yahoo Finance
ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
- Motley Fool
Is Johnson and Johnson Stock a Buy?
The healthcare giant's done well over the years, but will that continue amid its legal problems?
- Motley Fool
5 Dividend Kings to Buy and Hold Forever
The "forever" part means investors have to think about the longevity of payout growth as well as reliable payments.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Zacks
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
- Motley Fool
3 Dividend Stocks Ideal for Retirees
Dividend stocks are a great option for a retirement account since you're earning income simply for holding shares. The coronavirus pandemic caused many companies to cut or cancel dividends. While other businesses saw substantial revenue declines from the current economic slowdown, there were at least three that delivered revenue and dividend increases in these tough economic times.
- Motley Fool
If You're Retired, Consider Buying These 3 Stocks
Solid balance sheets, operations in critical industries, and rising dividends. What's not to love?
- Motley Fool
Is Arrowhead Pharmaceuticals a Buy?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
- Yahoo Finance
An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
- Yahoo Finance
Some wellness products growing ‘over 1,000%’ during pandemic: Ro CEO
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- Yahoo Finance
The race for a coronavirus treatment is fanning fears of 'vaccine nationalism'
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
- Zacks
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
